King Pharmaceuticals And Palatin Technologies Announce End-of-Phase 2 Meeting With FDA For Bremelanotide
Palatin Technologies, Inc. (Amex: PTN) and King Pharmaceuticals, Inc. (NYSE: KG) announced today that the U.S. Food and Drug Administration (FDA) has scheduled an End-of-Phase 2 meeting to discuss clinical study results with bremelanotide for the treatment of erectile dysfunction (ED). Palatin Technologies submitted a meeting request to FDA in May 2007; FDA has scheduled the meeting for August 2007.
